CNS Drugs

, Volume 17, Issue 12, pp 853–867 | Cite as

Neural Transplantation in Patients with Huntington’s Disease

Leading Article


The gene for Huntington’s disease was identified in 1993 as being a CAG repeat expansion in exon 1 of a gene now known as huntingtin on chromosome 4. Although many of the downstream effects of this mutant gene were identified in the subsequent years, a more detailed understanding of these events will be necessary in order to design specific interventions to interfere with the disease process and slow disease progression.

In parallel, a number of groups have been investigating alternative approaches to treatment of Huntington’s disease, including cell and tissue transplantation. As the brunt of cell dysfunction and loss is borne by the striatum, at least in the early to mid-stages of disease, the goal is to identify methods for replacing lost cells with fetal neuroblasts that can develop, integrate into the host circuitry and thereby restore lost function. Clinical studies in which primary fetal neuroblasts were transplanted into the brains of patients with advanced Parkinson’s disease have demonstrated benefit when the transplant methodology closely follows the biological principles established in animal experiments.

On the basis of demonstrated benefit following striatal cell transplantation in animal models of Huntington’s disease, a small number of studies have now commenced in patients with Huntington’s disease. To date, these clinical studies have demonstrated the feasibility and safety of transplantation in this condition, but it will require several more years yet before the efficacy of the procedure can be confidently established.



Professor Rosser is a Lister Institute Clinical Research Fellow. Professor Dunnett is a Cardiff Professorial Research Fellow. Their UK studies in cell transplantation are funded by the Medical Research Council (MRC), Huntington’s Disease Association (HDA) of the UK, Parkinson’s Disease Society (PDS) and Wellcome Trust. The authors declare no conflicts of interest relevant to this review.


  1. 1.
    Harper PS. Huntington’s disease. 2nd ed. London: WB Saunders, 1996Google Scholar
  2. 2.
    Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain 1998; 121(7): 1329–43PubMedCrossRefGoogle Scholar
  3. 3.
    Van Vugt JP, Van Hilten BJ, Roos RA. Hypokinesia in Huntington’s disease. Mov Disord 1996; 11(4): 384–8PubMedCrossRefGoogle Scholar
  4. 4.
    Brandt J, Butters N. Neuropsychological characteristics of Huntington’s disease. In: Grant I, Adams KM, editors. Neuropsychological assessment of neuropsychiatric disorders. Oxford: Oxford University Press, 1996: 321–41Google Scholar
  5. 5.
    Lawrence AD, Sahakian BJ, Robbins TW. Cognitive functions and corticostriatal circuits: insights from Huntington’s disease. Trends Cogn Sci 1998; 2: 379–88PubMedCrossRefGoogle Scholar
  6. 6.
    Vonsattel J-P, Myers RH, Stevens TJ. Neuropathologic classification of Huntington’s disease. J Neuropathol Exp Neurol 1985; 44: 559–77PubMedCrossRefGoogle Scholar
  7. 7.
    A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes: Huntington’s Disease Collaborative Research Group. Cell 1993; 72: 971–83CrossRefGoogle Scholar
  8. 8.
    Harper PS, Perutz M. Glutamine repeats and neurodegenerative diseases: molecular aspects. Oxford: Oxford University Press, 2001Google Scholar
  9. 9.
    Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3): 537–48PubMedCrossRefGoogle Scholar
  10. 10.
    DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990–3PubMedCrossRefGoogle Scholar
  11. 11.
    Beal MF. Huntington’s disease, energy, and excitotoxicity. Neurobiol Aging 1994; 15: 275–6PubMedCrossRefGoogle Scholar
  12. 12.
    Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett 2001; 315(3): 149–53PubMedCrossRefGoogle Scholar
  13. 13.
    Kieburtz K, Koroshetz W, McDermott M, et al. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57(3): 397–404Google Scholar
  14. 14.
    Rosser A, Dunnett S. New drugs for Huntington’s disease. Neuroreport 2002; 13(2): A21–2CrossRefGoogle Scholar
  15. 15.
    Emerich DF, Winn SR, Hantraye P, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 1997; 386(6623): 395–9PubMedCrossRefGoogle Scholar
  16. 16.
    Bachoud-Lévi AC, Deglon N, N’Guyen JP, et al. Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2001; 11(12): 1723–9CrossRefGoogle Scholar
  17. 17.
    Dunnett SB, Mayer E. Neural grafts, growth factors and trophic mechanisms of recovery. In: Hunter AJ, Clarke M, editors. Neurodegeneration. New York: Academic Press, 1992: 183–217Google Scholar
  18. 18.
    Rosser AE, Dunnett SB. Neural transplantation for the treatment of Huntington’s disease. In: Krauss JK, Jankovic J, Grossman RG, editors. Movement disorders surgery. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 353–73Google Scholar
  19. 19.
    Piccini P, Brooks DJ, Björklund A, et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson’s patient. Nat Neurosci 1999; 2: 1137–40PubMedCrossRefGoogle Scholar
  20. 20.
    Peschanski M, Césaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington’s disease. Neuroscience 1995; 68(2): 273–85PubMedCrossRefGoogle Scholar
  21. 21.
    Bachoud-Lévi AC, Hantraye P, Peschanski M. Fetal neural grafts for Huntington’s disease: a prospective view. Mov Disord 2002; 17(3): 439–44PubMedCrossRefGoogle Scholar
  22. 22.
    Freeman TB, Hauser RA, Willing AE, et al. Transplantation of human fetal striatal tissue in Huntington’s disease: rational for clinical studies: neural transplantation in neurodegenerative disease. Novartis symposium no. 231; 1999 Oct 12-14; London. London: Novartis Foundation, 2000: 129–38Google Scholar
  23. 23.
    Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson’s disease. Prog Brain Res 2000; 127: 299–320PubMedCrossRefGoogle Scholar
  24. 24.
    Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996; 19(3): 102–9PubMedCrossRefGoogle Scholar
  25. 25.
    Dunnett SB, Björklund A, Lindvall O. Cell therapy in Parkinson’s disease: stop or go? Nat Rev Neurosci 2001; 2: 365–9PubMedCrossRefGoogle Scholar
  26. 26.
    Dunnett SB, Björklund A. Mechanisms of function of neural grafts in the injured brain. In: Dunnett SB, Björklund A, editors. Functional neural transplantation. New York: Raven Press, 1994: 531–67Google Scholar
  27. 27.
    Sanberg PR, Borlongan CV, Wictorin K, et al. Fetal tissue transplantation for Huntington’s disease: preclinical studies. In: Freeman TB, Kordower JH, editors. Cell transplantation for neurological disorders. Totowa (NJ): Humana Press, 1998: 77–93CrossRefGoogle Scholar
  28. 28.
    Lindvall O. Prospects of transplantation in human neurodegenerative diseases. Trends Neurosci 1991; 14: 376–84PubMedCrossRefGoogle Scholar
  29. 29.
    Quinn NP, Brown R, Craufurd D, et al. Core assessment programme for intracerebral transplantation in Huntington’s disease (CAPIT-HD). Mov Disord 1996; 11(2): 143–50PubMedCrossRefGoogle Scholar
  30. 30.
    Shannon KM, Kordower JH. Neural transplantation for Huntington’s disease: experimental rationale and recommendations for clinical trials. Cell Transplant 1996; 5(2): 339–52PubMedCrossRefGoogle Scholar
  31. 31.
    Barker RA, Dunnett SB. Neural repair, transplantation and rehabilitation. Hove (UK): The Psychology Press, 1999Google Scholar
  32. 32.
    Coyle JT, Schwarcz R. Lesions of striatal neurons with kainic acid provides a model for Huntington’s chorea. Nature 1976; 263: 244–6PubMedCrossRefGoogle Scholar
  33. 33.
    Ferrante RJ, Kowall NW, Cipolloni PB, et al. Excitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization. Exp Neurol 1993; 119: 46–71PubMedCrossRefGoogle Scholar
  34. 34.
    Sladek JR, Shoulson I. Neural transplantation: a call for patience rather than patients. Science 1988; 240: 1386–8PubMedCrossRefGoogle Scholar
  35. 35.
    Palfi SP, Ferrante RJ, Brouillet E, et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington’s disease. J Neurosci 1996; 16(9): 3019–25PubMedGoogle Scholar
  36. 36.
    Sanberg PR, Coyle JT. Scientific approaches to Huntington’s disease. CRC Crit Rev Clin Neurobiol 1984; 1: 1–44PubMedGoogle Scholar
  37. 37.
    Divac I, Öberg RGE. The neostriatum. Oxford: Pergamon Press, 1979Google Scholar
  38. 38.
    Kendall AL, Rayment FD, Torres EM, et al. Functional integration of striatal allografts in a primate model of Huntington’s disease. Nat Med 1998; 4(6): 727–9PubMedCrossRefGoogle Scholar
  39. 39.
    Palfi S, Condé F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington’s disease. Nat Med 1998; 4(8): 963–6PubMedCrossRefGoogle Scholar
  40. 40.
    Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493–506PubMedCrossRefGoogle Scholar
  41. 41.
    Carter RJ, Lione LA, Humby T, et al. Characterisation of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 1999; 19(8): 3248–57PubMedGoogle Scholar
  42. 42.
    Lione LA, Carter RJ, Bates GP, et al. Selective discrimination learning impairments in mice expressing the human Huntington’s disease mutation. J Neurosci 1999; 19(23): 10428–37PubMedGoogle Scholar
  43. 43.
    Morton AJ, Edwardson JM. Progressive depletion of complexin II in a transgenic mouse model of Huntington’s disease. J Neurochem 2001; 76(1): 166–72PubMedCrossRefGoogle Scholar
  44. 44.
    Davies SW, Turmaine M, Cozens BA, et al. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci 1999; 354(1386): 981–9CrossRefGoogle Scholar
  45. 45.
    Goldberg YP, Kalchman MA, Metzler M, et al. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum Mol Genet 1996; 5(2): 177–85PubMedCrossRefGoogle Scholar
  46. 46.
    Martindale D, Hackam AS, Wieczorek A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18: 150–4PubMedCrossRefGoogle Scholar
  47. 47.
    Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998; 20: 198–202PubMedCrossRefGoogle Scholar
  48. 48.
    Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999; 8: 397–407PubMedCrossRefGoogle Scholar
  49. 49.
    Wheeler VC, Auerbach W, White JK, et al. Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet 1999; 8: 115–22PubMedCrossRefGoogle Scholar
  50. 50.
    Dunnett SB, Carter RJ, Watts C, et al. Striatal transplantation in a transgenic mouse model of Huntington’s disease. Exp Neurol 1998; 154: 31–40PubMedCrossRefGoogle Scholar
  51. 51.
    van Dellen A, Deacon R, York D, et al. Anterior cingulate cortical transplantation in transgenic Huntington’s disease mice. Brain Res Bull 2001; 56(3-4): 313–8PubMedCrossRefGoogle Scholar
  52. 52.
    Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992; 38: 611–39PubMedCrossRefGoogle Scholar
  53. 53.
    Björklund A, Campbell K, Sirinathsinghji DJS, et al. Functional capacity of striatal transplants in the rat Huntington model. In: Dunnett SB, Björklund A, editors. Functional neural transplantation. New York: Raven Press, 1994: 157–95Google Scholar
  54. 54.
    Graybiel AM, Liu FC, Dunnett SB. Intrastriatal grafts derived from fetal striatal primordia. I: phenotypy and modular organization. J Neurosci 1989; 9: 3250–71Google Scholar
  55. 55.
    Clarke DJ, Wictorin K, Dunnett SB, et al. Internal composition of striatal grafts: light and electron microscopy. In: Percheron G, McKenzie JS, Féger J, editors. The basal ganglia IV: new ideas on structure and function. New York: Plenum Press, 1994: 189–96Google Scholar
  56. 56.
    Sirinathsinghji DJS, Mayer E, Fernandez JM, et al. The localisation of CCK mRNA in embryonic striatal tissue grafts: further evidence for the presence of non-striatal cells. Neuroreport 1993; 4: 659–62PubMedCrossRefGoogle Scholar
  57. 57.
    Rutherford A, Garcia-Muñoz M, Dunnett SB, et al. Electrophysiological demonstration of host cortical inputs to striatal grafts. Neurosci Lett 1987; 83: 275–81PubMedCrossRefGoogle Scholar
  58. 58.
    Xu ZC, Wilson CJ, Emson PC. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J Neurophysiol 1991; 65: 477–93PubMedGoogle Scholar
  59. 59.
    Campbell K, Wictorin K, Björklund A. Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afférents. Proc Natl Acad Sci U S A 1992; 89: 10489–93PubMedCrossRefGoogle Scholar
  60. 60.
    Sirinathsinghji DJS, Dunnett SB, Isacson O, et al. Striatal grafts in rats with unilateral neostriatal lesions. II: in vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 1988; 24: 803–11Google Scholar
  61. 61.
    Dunnett SB, Nathwani F, Björklund A. The integration and function of striatal grafts. Prog Brain Res 2000; 127: 345–80PubMedCrossRefGoogle Scholar
  62. 62.
    Deckel AW, Robinson RG, Coyle JT, et al. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington’s disease by day 18 fetal striatal implants. Eur J Pharmacol 1983; 92: 287–8Google Scholar
  63. 63.
    Isacson O, Brundin P, Kelly PAT, et al. Functional neuronal replacement by grafted striatal neurons in the ibotenic acid lesioned rat striatum. Nature 1984; 311: 458–60PubMedCrossRefGoogle Scholar
  64. 64.
    Isacson O, Dunnett SB, Björklund A. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc Natl Acad Sci U S A 1986; 83: 2728–32PubMedCrossRefGoogle Scholar
  65. 65.
    Dunnett SB, Isacson O, Sirinathsinghji DJS, et al. Striatal grafts in rats with unilateral neostriatal lesions. III: recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience 1988; 24: 813–20Google Scholar
  66. 66.
    Fricker RA, Torres EM, Hume SP, et al. The effects of donor stage on the survival and function of embryonic striatal grafts. II: correlation between positron emission tomography and reaching behaviour. Neuroscience 1997; 79: 711–22Google Scholar
  67. 67.
    Montoya CP, Astell S, Dunnett SB. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog Brain Res 1990; 82: 459–66PubMedCrossRefGoogle Scholar
  68. 68.
    Boer GJ. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J Neurol 1994; 242: 1–13PubMedCrossRefGoogle Scholar
  69. 69.
    Polkinghorne J, Hoffenberg R, Kennedy I, et al. Review of the guidance on the research use of fetuses and fetal material. London: HMSO, 1989Google Scholar
  70. 70.
    Widner H, Albanese A, Aebischer P, et al. NIH neural transplantation funding [letter]. Science 1994; 263: 737PubMedCrossRefGoogle Scholar
  71. 71.
    Freeman TB, Vawter D, Goetz CG, et al. The use of cosmetic surgical placebo controlled trial in the treatment of Parkinson’s disease [abstract]. Abstr Soc Neurosci 1995; 21: 1756Google Scholar
  72. 72.
    Freeman TB, Vawter D, Goetz CG, et al. Fetal mesencephalic transplants in Parkinson’s disease: indications for the use of a cosmetic surgical placebo-controlled protocol [letter]. Exp Neurol 1995; 135: 164Google Scholar
  73. 73.
    Peschanski M, Defer G, Dethy S, et al. Towards a phase III multicenter study of fetal ventral mesencephalic transplants in patients with late-stage Parkinson’s disease. In: Freeman TB, Widner H, editors. Cell transplantation for neurological disorders. Towata (NJ): Humana Press, 1998: 31–43CrossRefGoogle Scholar
  74. 74.
    Freeman TB, Vawter DE, Leaverton PE, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson’s disease. N Engl J Med 1999; 341(13): 988–92PubMedCrossRefGoogle Scholar
  75. 75.
    Freed CR, Breeze RE, Fahn S. Placebo surgery in trials of therapy for Parkinson’s disease. N Engl J Med 2000; 342(5): 353–4PubMedCrossRefGoogle Scholar
  76. 76.
    Dekkers W, Boer GJ. Sham neurosurgery in patients with Parkinson’s disease: is it morally acceptable? J Med Ethics 2001; 27(3): 151–6PubMedCrossRefGoogle Scholar
  77. 77.
    Boer GJ, Widner H. Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res Bull 2002 Sep 30; 58(6); 547–53PubMedCrossRefGoogle Scholar
  78. 78.
    Rosser AE, Barker RA, Harrower T, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatr 2002; 73: 678–85PubMedCrossRefGoogle Scholar
  79. 79.
    Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001; 344(10): 710–9PubMedCrossRefGoogle Scholar
  80. 80.
    Kawamoto JC, Barrett JN. Cryopreservation of primary neurons for tissue culture. Brain Res 1986; 384(1): 84–93PubMedCrossRefGoogle Scholar
  81. 81.
    Sauer H, Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Restor Neurol Neurosci 1991; 2: 123–35PubMedGoogle Scholar
  82. 82.
    Hurrelbrink CB, Armstrong RJE, Barker RA, et al. Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington’s disease. Cell Transplant 2000; 9(6): 437–749Google Scholar
  83. 83.
    Olsson M, Björklund A, Campbell K. Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence. Neuroscience 1998; 84: 867–76PubMedCrossRefGoogle Scholar
  84. 84.
    Pakzaban P, Deacon TW, Burns LH, et al. Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp Brain Res 1993; 97: 13–22PubMedCrossRefGoogle Scholar
  85. 85.
    Deacon TW, Pakzaban P, Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res 1994; 668: 211–9PubMedCrossRefGoogle Scholar
  86. 86.
    Watts C, Brasted PJ, Eagle DM, et al. Embryonic donor age and dissection influence striatal graft development and functional integration in a rodent model of Huntington’s disease. Exp Neurol 2000; 163: 85–97PubMedCrossRefGoogle Scholar
  87. 87.
    Grasbon-Frodl EM, Nakao N, Lindvall O, et al. Developmental features of human striatal tissue transplanted in a rat model of Huntington’s disease. Neurobiol Dis 1997; 3: 299–311PubMedCrossRefGoogle Scholar
  88. 88.
    Kendall AL, Hantraye P, Palfi S. Striatal tissue transplantation in non-human primates. Prog Brain Res 2000; 127: 381–401PubMedCrossRefGoogle Scholar
  89. 89.
    Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology 2002; 58(5): 687–95PubMedCrossRefGoogle Scholar
  90. 90.
    Fricker RA, Barker RA, Fawcett JW, et al. A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures and in vivo grafts. Cell Transplant 1996; 5(6): 599–611PubMedCrossRefGoogle Scholar
  91. 91.
    Watts C, Brasted PJ, Dunnett SB. The morphology, integration and functional efficacy of striatal grafts differs between cell suspensions and tissue pieces. Cell Transplant 2000; 9(3): 395–407PubMedGoogle Scholar
  92. 92.
    Dunnett SB, Björklund A, Schmidt RH, et al. Intracerebral grafting of neuronal cell suspensions.V: behavioral recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol Scand Suppl 1983; 522: 39–47PubMedGoogle Scholar
  93. 93.
    Dunnett SB, Björklund A, Schmidt RH, et al. Intracerebral grafting of neuronal cell suspensions.IV: behavioral recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand Suppl 1983; 522: 29–37PubMedGoogle Scholar
  94. 94.
    Langsten JW, Widner H, Goetz CG. Core assessment program for intracerebral transplantation (CAPIT). Mov Disord 1992; 7: 2–13CrossRefGoogle Scholar
  95. 95.
    Kieburtz K, Penney JB, Como P, et al. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11(2): 136–42CrossRefGoogle Scholar
  96. 96.
    Piccini P, Lindvall O, Björklund A, et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann Neurol 2000; 48(5): 689–95PubMedCrossRefGoogle Scholar
  97. 97.
    Pavese N, Andrews TC, Brooks DJ, et al. Huntington’s disease progression measured with serial [11C]-raclopride PET and the UHDRS [abstract]. Neurology 2001; 56(6): A385Google Scholar
  98. 98.
    Labandeira-Garcia JL, Wictorin K. Development and integration of intrastriatal striatal grafts implanted into long-term ibotenate lesions. J Neural Transplant Plast 1992; 3(4): 181–2CrossRefGoogle Scholar
  99. 99.
    Labandeira-Garcia JL, Wictorin K, Cunningham ET, et al. Development of intrastriatal striatal grafts and their afferent innervation from the host. Neuroscience 1991; 42: 407–26PubMedCrossRefGoogle Scholar
  100. 100.
    Watts C, Dunnett SB. Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington’s disease: implications for timing of surgical development. J Neurosurg 1998; 89: 367–74Google Scholar
  101. 101.
    Sramka M, Rattaj M, Molina H, et al. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington’s chorea. Stereotact Funct Neurosurg 1992; 58: 79–83PubMedCrossRefGoogle Scholar
  102. 102.
    Madrazo I, Franco-Bourland RE, Castrejon H, et al. Fetal striatal homotransplantation for Huntington’s disease: first two case reports. Neurol Res 1995; 17(4): 312–5PubMedGoogle Scholar
  103. 103.
    Kopyov OV, Jacques S, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington’s disease patients. Exp Neurol 1998; 119: 97–108CrossRefGoogle Scholar
  104. 104.
    Philpott LM, Kopyov OV, Lee AJ, et al. Neuropsychological functioning following fetal striatal transplantation in Huntington’s chorea: three case presentations. Cell Transplant 1997; 6: 203–12PubMedCrossRefGoogle Scholar
  105. 105.
    Kopyov OV, Jacques S, Kurth M, et al. Fetal transplantation for Huntington’s disease: clinical studies. In: Freeman TB, Kordower JH, editors. Cell transplantation for neurological disorders. Totowa (NJ): Humana Press, 1998: 95–134CrossRefGoogle Scholar
  106. 106.
    Bachoud-Lévi AC, Bourdet C, Brugières P, et al. Safety and tolerability assessment of intrastriatal neural allografts in Huntington’s disease patients. Exp Neurol 2000; 161: 194–202PubMedCrossRefGoogle Scholar
  107. 107.
    Freeman TB, Cicchetti F, Hauser RA, et al. Transplanted fetal striatum in Huntington’s disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 2002; 97: 13877–82CrossRefGoogle Scholar
  108. 108.
    Bachoud-Lévi AC, Rémy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington’s disease after neural transplantation. Lancet 2000; 356(9246): 1975–9PubMedCrossRefGoogle Scholar
  109. 109.
    Deacon T, Schumacher J, Dinsmore J, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson’s disease. Nat Med 1997; 3(3): 350–3PubMedCrossRefGoogle Scholar
  110. 110.
    Dunnett SB, Annett LE, Kendall AL, et al. Sources of cells for transplantation and gene therapy in Parkinson’s disease. In:Teelken AW, Korf J, editors. Neurochemistry. New York: Plenum Press, 1997: 249–57CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.School of BiosciencesCardiff UniversityWalesUK
  2. 2.Department of NeurologyUniversity of Wales College of MedicineCardiffUK

Personalised recommendations